Patents by Inventor John T. Sisko
John T. Sisko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130203735Abstract: The present invention is directed to caprolactams which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.Type: ApplicationFiled: October 24, 2011Publication date: August 8, 2013Inventors: John T. Sisko, Thomas J. Tucker, Robert M. Tynebor
-
Patent number: 8404856Abstract: Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: November 14, 2008Date of Patent: March 26, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Thomas J. Tucker, Robert Tynebor, John T. Sisko, Neville Anthony, Robert Gomez, Samson M. Jolly
-
Publication number: 20100256181Abstract: Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: November 14, 2008Publication date: October 7, 2010Inventors: Thomas J. Tucker, Robert Tynebor, John T. Sisko, Neville Anthony, Robert Gomez, Samson M. Jolly
-
Patent number: 7807684Abstract: Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: July 17, 2006Date of Patent: October 5, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Sandeep A. Saggar, John T. Sisko, Thomas J. Tucker, Robert M. Tynebor, Dai-Shi Su, Neville J. Anthony
-
Patent number: 7265134Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: August 13, 2002Date of Patent: September 4, 2007Assignee: Merck & Co., Inc.Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma, Jr.
-
Patent number: 7115597Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: October 2, 2003Date of Patent: October 3, 2006Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, Jr., John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Jr., Leonard Rodman
-
Publication number: 20040242637Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: February 17, 2004Publication date: December 2, 2004Inventors: George D Hartman, Thomas J Tucker, John T Sisko, Anthony M Smith, William C Lumma
-
Publication number: 20040192926Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: February 11, 2004Publication date: September 30, 2004Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma Jr
-
Publication number: 20040063720Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: October 2, 2003Publication date: April 1, 2004Applicant: Merck & Co., Inc.Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
-
Publication number: 20020137755Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: November 21, 2001Publication date: September 26, 2002Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
-
Patent number: 6376496Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.Type: GrantFiled: March 1, 2000Date of Patent: April 23, 2002Assignee: Merck & Co., Inc.Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Jeffrey M. Bergman
-
Patent number: 6358956Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including-farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.Type: GrantFiled: March 1, 2000Date of Patent: March 19, 2002Assignee: Merck & Co., Inc.Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Gerald E. Stokker
-
Patent number: 6355643Abstract: The present invention comprises unsubstituted and substituted piperazine-containing compounds having alkanoyl, alkylsulfonyl, alkylamido or alkoxycarbonyl substituents, and having the formula A, which inhibit prenyl-protein transferases. In particular, the invention relates to prenyl-protein transferase inhibitors which are efficacious in vivo as inhibitors of geranylgeranyl-protein transferase type I (GGTase-I) and that inhibit the cellular processing of both the H-Ras protein and the K4B-Ras protein. Such therapeutic compounds are useful in the treatment of cancer.Type: GrantFiled: March 1, 2000Date of Patent: March 12, 2002Assignee: Merck & Co., Inc.Inventors: William C. Lumma, John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Christopher J. Dinsmore, Jeffrey M. Bergman
-
Patent number: 6335343Abstract: The present invention comprises piperazine/piperazinone-containing compounds having multicyclic ring system substituents on one of the piperazine/piperazinone nitrogens, which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.Type: GrantFiled: March 1, 2000Date of Patent: January 1, 2002Assignee: Merck & Co., Inc.Inventors: William C. Lumma, Jr., Anthony M. Smith, John T. Sisko
-
Patent number: 6127390Abstract: The present invention is directed to compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.Type: GrantFiled: October 1, 1998Date of Patent: October 3, 2000Assignee: Merck & Co., Inc.Inventors: S. Jane deSolms, William C. Lumma, Jr., Anthony W. Shaw, John T. Sisko, Thomas J. Tucker
-
Patent number: 4963534Abstract: A process for rendering a bacterial polysaccharide soluble in aprotic solvents by exchanging the calcium counterion of a polysaccharide calcium salt for tetra-n-alkylammonium ion by precipitation.Type: GrantFiled: May 19, 1989Date of Patent: October 16, 1990Assignee: Merck & Co., Inc.Inventors: Ralph Calabria, Frederick W. Hartner, John T. Sisko